Acute Myeloid Leukemia: Focus on Novel Therapeutic Strategies

Acute myeloid leukemia (AML) is a heterogeneous disease with variable clinical outcomes. Cytogenetic analysis reveals which patients may have favorable risk disease, but 5-year survival in this category is only approximately 60%, with intermediate and poor risk groups faring far worse. Advances in o...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Tara L., Levy, M. Yair
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3362331/
https://www.ncbi.nlm.nih.gov/pubmed/22654526
http://dx.doi.org/10.4137/CMO.S7244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3362331/
https://www.ncbi.nlm.nih.gov/pubmed/22654526
http://dx.doi.org/10.4137/CMO.S7244

Ejemplares similares